In our study, ASXL1 mutation apparently associated with resistance to venetoclax in combination with A1331825, but not in combination with S63845 or bimiralisib, possibly due to the presence of concurrent mutations in KRAS, PTPN11, RUNX1, or TP53 genes in the primary AML samples. The gene discussed is KRAS; the disease is acute myeloid leukemia.